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ABSTRACT  Electron  microscopy of myosin-II molecules and filaments reacted with monoclonal 
antibodies demonstrates directly where the antibodies  bind and shows that certain antibodies 
can  inhibit the polymerization  of myosin-II  into filaments.  The binding  sites of seven of 23 
different monoclonal  antibodies  were localized  by platinum  shadowing of myosin monomer- 
antibody  complexes.  The  antibodies  bind  to  a variety  of sites on  the  myosin-II  molecule, 
including  the heads, the proximal  end of the tail near the junction of the heads and tail, and 
the tip of the tail. The binding sites of eight of the 23 antibodies were also localized on myosin 
filaments  by  negative staining. Antibodies  that  bind  to  either the  myosin  heads or to  the 
proximal  end of the tail decorate  the ends of the  bipolar  filaments.  Some of the antibodies 
that bind to the tip of the myosin-II tail decorate the bare zone of the myosin-II thin filament 
with  14-nm periodicity.  By combining the data from  these electron  microscope  studies and 
the  peptide mapping and competitive  binding  studies we have established the binding  sites 
of 16 of 23 monoclonal  antibodies.  Two of the 23 antibodies  block the formation  of myosin- 
II filaments and given sufficient  time,  disassemble preformed  myosin-II  filaments.  Both anti- 
bodies bind near one another at the tip of the myosin-II tail and are those that decorate the 
bare zone of preformed  bipolar filaments with 14-nm periodicity.  None of the other antibodies 
affect myosin filament  formation,  including  one that binds to another  site near the tip of the 
myosin-II  tail. This demonstrates that antibodies  can inhibit polymerization  of myosin-II,  but 
only when they bind to key sites on the tail of the molecule. 
Acanthamoeba  myosin-II has structural and enzymatic prop- 
erties that are thought to be essential for its presumed role in 
cell motility (16, 20). Myosin-II has two heads and a long tail 
and consists of two heavy chains (-175,000 mol wt) and four 
light chains (two each at -17,500 and -16,500 mol wt) that 
yield a  native molecular weight of ~400,000 mol wt.  Each 
head is made up of part of a heavy chain and two light chains. 
The tail is made up of the carboxy-terminal ends of  the heavy 
chains, presumably (by analogy to other myosins) arranged 
in alpha-helical coiled coils. In low salt, myosin-II molecules 
aggregate laterally to form small bipolar filaments similar to 
the  larger  bipolar  filaments  formed  by  other  cytoplasmic 
myosins and by muscle myosins (18).  The myosin-II heads 
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contain the ATP- (17) and actin-binding sites (20). By analogy 
to  muscle,  the  heads  are  believed  to  have  the  enzymatic 
activity responsible  for mechanochemical energy transduc- 
tion. The aggregation of tails to form bipolar filaments pre- 
sumably allows myosin-II molecules to act in a polarized and 
concerted fashion during their interaction with actin to pro- 
duce force. 
It has not yet been possible to cleave myosin-II with pro- 
teases into distinct functional domains like muscle myosin 
subfragment-1, heavy meromyosin, subfragment-2,  or light 
meromyosin (3).  For example, brief digestion with  trypsin 
cleaves the myosin-II heavy chain at a single site somewhere 
in the head but the two resulting polypeptides (70,000 and 
1015 105,000  mol  wt)  can  only  be  separated  under  denaturing 
conditions. As a result, the functional properties of  the various 
structural domains cannot be discerned by a strictly biochem- 
ical approach. 
To sort out the functions of the various parts of myosin-II, 
we  prepared  and  characterized  23  monoclonal  antibodies 
against  the  myosin-II heavy  chain  (10).  These  antibodies 
recognize at least 15 unique antigenic determinants and can 
be grouped into six families whose members are related by 
the proximity of their binding sites on the  myosin-II heavy 
chain.  They  offer a  unique  opportunity  to  determine  the 
function  of each  domain  within  the  context  of the  whole 
myosin molecule. 
Here we localize the binding site of four of the six antibody 
families on myosin-II  and evaluate the ability of  each antibody 
to block myosin-II  filament formation. Antibody-binding sites 
on the heads, on the proximal part of the tail near its junction 
with the heads, and at the tip of the tail were all localized on 
individual myosin molecules by electron microscopy of plat- 
inum-shadowed  antibody-myosin  complexes.  Antibodies 
were localized on myosin-II filaments reacted with antibody 
by electron microscopy of negatively stained preparations. By 
electron microscopy, we also demonstrate that two of the 23 
antibodies inhibit the formation of myosin-II filaments and 
can  slowly  disassemble  preformed  filaments.  As  might  be 
expected, these antibodies belong to the family that binds to 
the tip of the myosin-II tail. Antibodies that bind to the tail 
close to the heads do not prevent polymerization. The struc- 
tural information that these studies provide are essential for 
the interpretation of antibody inhibition of myosin-II ATPase 
activity and contraction of gels of amoeba cytoplasm (11,  12). 
Preliminary accounts of this work were presented at meet- 
ings of the American Society for Cell Biology and the Bio- 
physical Society (7-9). 
MATERIALS AND  METHODS 
Myosin-II purification,  the production  and purification  of monoclonal  anti- 
bodies, and the sources of most reagent grade chemicals were described previ- 
ously (10). Glycerol and ammonium formate were obtained  from J. T. Baker 
(Phillipsburg, N  J). 
Each antibody  is named according to its eliciting antigen (M2 for myosin- 
II), followed by a unique integer suffix that designates the individual clone that 
produces it (10). 
Platinum Shadowing of Antibody-Myosin Complexes:  The 
antibody-binding  sites on the myosin-II molecule were determined  by rotary 
shadowing antibody-myosin complexes dried from glycerol (5, 6, 22). Myosin- 
II (0.5-3.5  uM in 0.6 M ammonium formate, pH 7.5) was mixed with a small 
volume (typically 6% or less of the total volume of the mixture,  to minimize 
sucrose concentration  in the final sample) of antibody in 20% sucrose, 5 mM 
imidazole, pH 7.0, 3 mM NAN3. The molar ratio of antibody to myosin varied 
from  1 to  10.  The samples were diluted  with  ammonium formate  to final 
myosin concentrations  of 0.05 to 0.5 t~M and mixed  1:1 with glycerol at room 
temperature. Samples were immediately sprayed onto freshly cleaved mica with 
an Effa Spray Mounter (Ernest F. Fullam,  Inc., Schenectady, NY) and dried 
under vacuum to  1-10  ×  10  -7 toll" at room temperature  for -60 min. The 
time between dilution  of samples into glycerol and spraying was typically <3 
min (see reference 23). Dried specimens were rotary-shadowed with platinum 
at an angle of 6", and stabilized with carbon. The carbon-platinum  replica was 
floated off the mica sheet and picked up from below on a 300 mesh copper 
grid. Electron  micrographs  were taken  on a JEOL 100 CX microscope  at x 
17,000, x  23,000, or x  28,000. 
The extent of antibody binding to myosin in platinum-shadowed specimens 
is detailed in Table I. Fields of  well spread myosin molecules were photographed 
at x  23,000 and negatives were enlarged 2.6-fold. Myosin-II molecules were 
scored for attached antibody and compared to molecules incubated with control 
antibodies against chicken skeletal muscle myosin that does not bind to myosin- 
1I (10). Approximately  1.6% of myosin molecules  complexed  with  control 
antibodies (Table I), but binding was to random regions of  the myosin molecule. 
1016  THE JOURNAL OF CELL BIOLOGY • VOLUME 99,  1984 
Such random binding  of specific antibodies was observed with the same low 
frequency. Frequency of specific binding shown in Table I refers to binding to 
the sites depicted in Figs. 1, 2, and 3. Typically ~25% of  the myosin molecules 
were not scored because they lacked sufficient contrast,  lacked some morpho- 
logical feature characteristic  of myosin,  or were parts of aggregates in which 
individual molecules were not discernable. 
The distance between the tip of the myosin-II tail and the antibody  M2.4 
binding site was measured  on prints enlarged x  6.05 with a lupe that had a 
scale interval of 0.1 mm. 
Negative Staining and Electron Microscopy:  Specimens were 
stained  on  glow-discharged, Formvar-coated,  carbon-coated  grids  with  1% 
uranyl acetate (18, 19). Electron micrographs were taken on a JEOL 100 CX 
microscope at magnifications of 23,000-46,000.  The periodicity of Fab M2.3 
decoration  of myosin filament bare zones was measured on prints enlarged x 
2.60 with the lupe described above. 
Filament Formation:  To evaluate antibody  effects on the polymeri- 
zation of myosin-II into thin filaments, we incubated 0.5 ~M myosin-lI with 2 
vM antibody in 300 mM KCI, 10 mM imidazole, pH 7.0 (a salt concentration 
that prevents polymerization) for 30 min and then diluted 20-fold into 20 mM 
KCI,  10  mM  imidazole,  pH  6.8, conditions  that cause  myosin-lI  to  form 
filaments.  After  30  s, 4  t*l of the diluted  sample  was placed  on a  grid and 
negatively stained. 
The effects of antibodies on the Mg÷*-induced aggregation of thin myosin- 
lI filaments into thick myosin-II filaments was tested in two ways. Starting with 
monomeric myosin preincubated  with antibody, samples were diluted into 20 
mM KCI, 10 mM MgCI2, and 10 mM imidazole, pH 7.0, conditions that favor 
the formation  of the thick  myosin-lI  filaments. Alternatively, myosin-ll  thin 
filaments  in 20  mM KCI were preincubated  with antibody  and MgCI2 was 
added to 10 mM. Samples were negatively stained. 
RESULTS 
Localization of Antibody-binding Sites on 
Individual Myosin-II Molecules 
Platinum-shadowed preparations of antibody-myosin com- 
plexes reveal the location of seven antibody-binding sites on 
myosin-II. By combining these electron  microscopic obser- 
vations with the data from antibody staining of one-dimen- 
sional  peptide  maps and  from competitive binding  studies 
(10), we establish the binding sites of 16 of the 23 monoclonal 
antibodies. 
Antibodies  That Bind to the Myosin-II Head 
Antibodies M2. l and M2.10 bind on or close to the myosin- 
II heads.  Platinum-shadowed specimens reveal myosin mol- 
ecules with extra heads and dimers and oligomers formed by 
head to head contacts of myosin molecules (Figs.  1 and  2, 
and Table I). It is possible that these antibodies bind on the 
myosin-II tails, directly adjacent to the heads.  However, no 
clearly resolvable stretches of tail were ever seen between the 
TABLE  I 
Frequency of Antibody Binding to Individual Myosin Molecules 
Percent 
molecules 
with anti- 
body  Number 
Antibody  bound  Binding site*  counted 
% 
M2.1  14.1 
M2.3  96.6 
M2.4  63.0 
M2.10  34.9 
M2.12  76.1 
Control antibody  1.6 
Heads  542 
Tip of tail  118 
Tail, adjacent to  138 
heads 
Heads  401 
Tip of tail  268 
Random  304 
* See Figs. I-3. Data compiled as described in Materials and Methods. FIGURE  1  Fields of rotary shadowed antibody-myosin-II complexes reveal two antibodies that bind on or near the myosin-II 
heads. Myosin-II in the presence of (a) a control antibody that does not bind to myosin-II, (b) antibody M2.1, and (c) antibody 
M2.10. Arrowheads point out some of the antibody-myosin-II complexes and are not meant to distinguish antibody molecules 
from myosin-II heads. Free antibody and free myosin molecules can be seen in each of the three fields. Bar, 200 nm. x  80,000. 
antibodies and the heads.  We conclude that both antibodies 
have binding sites either on the heads or on the tail so close 
to the heads that it is not feasible to resolve the difference. 
Antibodies That Bind to the Proximal End of the 
Myosin-II Tail Adiacent to Where It loins 
the Heads 
Antibodies  M2.4  (Figs.  2  and  3,  and  Table  I) and  M2.7 
(data not shown) bind to a region of  the myosin-II  tail adjacent 
to where the heads join the tail. Two other antibodies,  M2.6 
and -26, have not been directly localized by electron micros- 
copy, but we know that they bind to the same region of the 
myosin-II tail  because they stain  identical  peptides  on one- 
dimensional peptide  maps of myosin-II and are sufficiently 
close to M2.4  and -7 to completely inhibit their binding to 
myosin-II  (10).  In  the  presence  of antibody  M2.4  many 
myosin-II molecules appear to have four heads (Fig. 2 and 3). 
This demonstrates that the stoichiometry of  antibody binding 
can be 2:1. Judging from the length of  the tail, the real myosin 
heads are the two globular structures  at the end of the tail. 
These globular structures bind 71  +  6 nm (n =  50) from the 
tip of  the tail. Since the tail is -90 nm long (18), the antibodies 
must bind ~ 19 nm from the heads. At lower concentrations 
of antibody a  single antibody molecule binds, so the myosin 
has  three  globular  structures  at  the  end  of the  tail.  Again, 
there  are  no  comparable  images  when  myosin-II alone  or 
when  myosin-II in  the  presence  of control  antibodies  are 
examined (Figs.  1-3). 
Antibodies  M2.2,  -21,  -22,  and  -27  are  related  but  not 
identical to both M2.4, that binds to the proximal end of the 
myosin-II tails adjacent to the heads and to M2.10, that binds 
near or on the heads (10). These antibodies are related because 
in one-dimensional peptide  maps, antibodies M2.2,  -4, -10, 
-21, and -27 all bind to common peptides above ~ 18,000 mol 
wt.  Similarly,  these antibodies bind to the same peptides  as 
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M2.22 above -23,000 mol wt. As a consequence, even though 
we have not yet localized the binding sites of these antibodies 
by platinum-shadowing, we can be fairly certain about where 
they  bind  on  the  myosin-II molecule.  These  18,000-  and 
23,000-mol-wt peptides would be 20 and 26 nm long, respec- 
tively,  if  they  were  alpha-helical  coiled  coils.  Thus  these 
antibodies must bind either to the heads or the proximal 40 
nm of the tail. 
Antibodies That Bind to the Tip of the 
Myosin-II Tail 
Antibodies M2.3, -9, and -12 bind to the end of  the myosin- 
II tail (Figs. 2 and 3, and Table I). In no case was any myosin 
tail exposed distal to the antibody. At one end of the tail two 
myosin-II heads can be distinguished easily in favorable spec- 
imens. The other end of the tail usually has a single, globular 
bulge  on  it,  not  seen  in  preparations  of myosin-If alone, 
myosin-II mixed with nonspecific antibody, or myosin-II in 
the presence of the  19 other myosin-II specific monoclonal 
antibodies.  Occasionally  there  are  dimers  or  oligomers  of 
myosin-II that appeared  to be  myosin molecules linked tail 
to tail by one or more antibody molecules (Figs. 2 and 3, and 
Table  I).  Antibody  M2.8  must  also  bind  to  the  tip  of the 
myosin-I! tail because M2.8  specifically inhibits the binding 
of M2.3 to myosin-II and vice versa, and M2.3 and -8 stain 
similar constellations of myosin-II peptides (10). 
The micrographs suggest that two of these antibodies can 
bind to each myosin-II tail. The twofold symmetry of myosin 
suggests that at  least two antigenic sites should be available 
for antibody binding. In favorable specimens the bulge on the 
tip of the tail appears at least partially resolved into two lobes 
or domains (Figs. 2  and 3).  Further,  the mass at the end of 
the tail appears to vary somewhat, as if sometimes one and at 
other times two antibodies are bound. Finally, it is sometimes 
difficult to distinguish  between the myosin-II heads and the 
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and rotary-shadowing techniques. We have also been unable 
to localize the binding of the family that includes M2.5, -16, 
and  -19  or  the  family that  includes  M2.13,  -15,  and  -20. 
Antibody M2.11  stains alpha-chymotryptic peptide maps in 
a  pattern  identical to  the  staining pattern  seen with  M2. I. 
Unfortunately the smallest peptide stained is a  60,000-mol- 
wt peptide, so the binding may be in the head or somewhere 
on the tail. 
Antibody Decoration of Myosin-II Filaments 
Electron microscopy of myosin-ll filaments decorated with 
monoclonal antibodies provides additional information about 
the binding sites of some of the antibodies (Figs. 4 and 5). 
Control antibodies such as one that binds to skeletal muscle 
myosin, but not myosin-lI, do not affect the  appearance of 
the  myosin-II filaments,  except  the  background  uniformly 
accumulates less stain (Fig. 4). 
FIGURE  2  Selected  electron micrographs of individual antibody- 
myosin-II complexes. Numbers (M2.X) designate the specific mon- 
oclonal antibody used  in  each preparation. Antibodies M2.1  and 
-10 bind on or very near the myosin-II heads. Antibody M2.4 binds 
to the myosin-II tail, ~19 nm from the heads. Antibodies M2.3, -9, 
and -12 all bind to the tip of the myosin-II tail. The M2.12-myosin- 
II  complexes on  the  far  right  demonstrate that  it  is  sometimes 
difficult to distinguish myosin-II heads from antibodies bound to 
the tip of the tail. Dimers of myosin-II cross-linked by antibody are 
shown tail to tail (M2.3-myosin-II complex on  the far  right).  The 
control (C) is a preparation of myosin-II molecules with a threefold 
molar excess  of  Diana,  a  monodonal antibody  against  chicken 
pectoralis muscle myosin S-1  that does not bind to myosin-II. Bar, 
100 nm. x  130,000. 
antibodies bound  on the  opposite end of the  myosin-II tail 
(Fig. 2, especially M2.12, far right panels). 
Other Antibodies 
Antibodies M2.17  and  18 bind to the myosin-II head by 
biochemical criteria (10) but we have been unable to localize 
Antibody Binding to the Ends of the Bipolar 
Myosin-II Filaments 
Antibodies  M2.1,  -4,  - 10,  -17,  -18,  and  -26  bind  to  the 
myosin-heads projecting from the back-bone of the bipolar 
myosin-II filaments on either side of the bare zone (Fig.  4, 
data not shown for M2.17 and -26). The ends of the filaments 
are more massive than undecorated filaments, whether or not 
control antibodies that do not bind to myosin-lI are present 
(Fig. 4a). In no case did decoration of the ends of the bipolar 
filaments accentuate  the  15  nm  periodicity of the  myosin 
heads (18). Bipolar filaments whose ends were decorated with 
antibodies were indistinguishable from filaments formed from 
myosin-II monomers in the presence of the same antibodies. 
Fig. 4 also shows filaments decorated with M2.1  (Fig. 4c) and 
filaments formed in  the  presence of M2.1  (Fig.  4b).  In all 
other  cases  where  the  antibodies  decorate  the  ends  of the 
bipolar filaments such  as  M2.4,  -10,  -17,  -18,  and  -26 the 
filaments can  also  form from complexes of myosin-lI and 
antibody (Fig. 4). 
These observations confirm localization by platinum shad- 
owing and by peptide mapping. They establish that the bind- 
ing site for M2.1  is found in the amino-terminal region of the 
105,000-mol-wt heavy chain peptide (3,  10). In addition they 
are consistent with biochemical evidence that M2.17 and - 18 
bind  to  a  70,000-mol-wt  tryptic  peptide  of myosin-II that 
includes  the  amino-terminus of myosin and  is  part  of the 
myosin head (10). They demonstrate that M2.17 and -18 can 
bind  to  myosin  heads  when  the  myosin is  assembled into 
filaments. Finally, the similarity between filaments decorated 
with M2.1, -4, and -10 shows that negatively stained filament- 
antibody complexes can provide only approximate informa- 
tion about binding sites near the myosin-II heads. The reso- 
lution is not sufficient to distinguish between antibodies that 
bind to the head and those that bind to the tail close to the 
head. 
Antibody Binding to the Bare Zone  of the 
Myosin-II Filaments 
Antibodies M2.3, -9, and Fab fragments of M2.3 decorate 
the bare zone of preformed myosin-II filaments with striking 
periodicity (Fig.  5). Fab M2.3 molecules bind at an interval 
of 13.8 --- 1.6 nm (n =  93) with decoration on either side of 
the  filament  at  each  interval,  indicating  that  at  least  two 
1018  THE JOURNAL OF  CELL BIOLOGY • VOLUME 99,  1984 FIGURE  3  Fields of rotary shadowed antibody-myosin-ll complexes reveal the location of specific antibody-binding sites on the 
myosin-ll tail. Antibodies M2.3 (a), M2.9 (d), and M2.12 (e) all bind to the tip of the myosin tail. Antibody M2.4 (c) binds to the 
myosin-ll tail, ~19 nm from the heads. A control preparation (b) of myosin-ll alone is identical to myosin-ll in the presence of 
control antibodies that do not bind to myosin-ll (compare with Fig. I a). Arrowheads point out some of the antibody-myosin-ll 
complexes. Bar, 200 nm. x  80,000. 
myosin molecules are in perfect register.  Up to six rows of 
antibody molecules can be observed in favorable specimens. 
This  is  consistent  with  there  being  at  least  12  myosin-II 
molecules in each thin bipolar filament (18).  In the case of 
M2.9, decoration results in extensive lateral cross-linking with 
the antibody molecules forming regular "rungs" in a ladder- 
like arrangement (data not shown). Antibody M2.12,  which 
also binds to the tip of the myosin-II tail (Figs. 2 and 3), does 
not appear to decorate the bare zone of the bipolar filaments. 
Periodic binding of antibody M2.3 and -9 on the bare zone 
indicates the longitudinal position of the tips of the myosin- 
II tails in the myosin-II thin  filaments. The  13.8  +  1.6-nm 
periodicity is also in close agreement with the 15-nm spacing 
of myosin-I| heads at the ends of the bipolar filaments (l 8). 
It shows that the tips of some of  the myosin-II  tails are exposed 
on or near the surface of the filament and that at least two 
myosin molecules are in longitudinal register at each binding 
site along the filament. 
KIEHART ET AL  Monoclonal  Antibody-binding  Sites on  Acanthamoeba  ] 0] 9 FIGURE 4  Electron micrographs of negatively stained  preparations of myosin-II  filament-antibody complexes demonstrate that 
several antibodies bind to the ends of the bipolar myosin filaments. (b, c, d, e, and f) Decorated filaments formed from monomer 
in  the  presence  of  control  antibodies  or  antibodies  M2.1,  °4,  -10,  and  -18,  respectively.  Such  decorated  filaments  were 
indistinguishable from decorated filaments formed by the addition of antibody to preformed filaments (compare M2.1  decorated 
filaments in b and c).  Bar, 100 nm. x  109,000. 
Effect of Monoclonal Antibodies  on 
Myosin-II Polymerization 
Most of the  antibodies  have  no effect  on polymerization. 
Monomeric myosin-II  was preincubated  with a  fourfold ex- 
cess of antibody or Fab fragments, the salt concentration was 
lowered  to  favor  assembly  and  specimens  were  negatively 
stained in preparation for electron microscopy. The absolute 
concentration of antibody was 2 ~M, a concentration at least 
50-fold  greater  than  the  apparent  dissociation  constant  we 
measured for these antibodies (10). Normal filaments formed 
FIGURE  5  Fab fragments of antibody M2.3 decorate the bare zones 
of bipolar myosin-II thin filaments and prevent the Mg+%induced 
aggregation of thin  myosin-II filaments into thick filaments. (a) A 
high  magnification view of negatively stained myosin-II thin  fila- 
ments decorated with Fab fragments of M2.3.  Preformed myosin-II 
filaments were  preincubated with  a 4  fold  molar excess of  Fab 
fragments of antibody M2.3. Mg  ÷÷, added to favor the formation of 
thick myosin-II filaments also slows antibody induced depolymeri- 
zation of the thin  bipolar filaments (12). Hash  marks indicate the 
periodicity of antibody decoration of the thin myosin-II filaments. 
Bar, 50  nm.  x  191,000.  (b) A  low power micrograph of a similar 
specimen prepared as described in a. Fab M2.3 prevents aggrega- 
tion of thin filaments and decorates their bare zones with  14 nm 
periodicity (indicated by dots).  The wispy appearance of the fila- 
ments reflects  the ability of M2.3 to induce the slow depolymeri- 
zation of the myosin-II filaments (12). (c} An electron micrograph of 
a control preparation that contains myosin-II and a fourfold molar 
excess of Diana, a monoclonal antibody against chicken pectoralis 
subfragment-1  that does not bind to myosin-II and  that does not 
prevent  aggregation of  thin  filaments  into  thick  filaments  upon 
addition of Mg  ÷+ to  10  mM. Arrowheads point out  undecorated 
thin bipolar myosin-II filaments (in equilibrium with thick filaments) 
for comparison to antibody-decorated filament in a and b. (b and 
c) Bar, 100 nm. x  87,000. 
10~)0  THE JOURNAL OF  CELL BIOLOGY • VOLUME 99,  1984 FIGURE  6  Antibodies M2.3 and M2.9 block myosin-II polymerization. Monomeric myosin was preincubated with a 4 fold molar 
excess of antibody and then diluted into 20 mM KCI to cause polymerization. (a and b) Antibodies M2.3 and M2.9, which bind 
to the tip of the myosin tail, blocked filament formation. Filaments were never seen on any of the grids prepared. (c) In contrast, 
antibody M2.12, another antibody that binds to the tip of the tail, allows normal polymerization. Filaments also form normally in 
the presence of control antibodies that do not bind to myosin-II, other antibodies that bind to the tail near the heads (M2.4), and 
antibodies that bind to the heads  (M2.1,  10 and  18, see Fig. 4).  In these experiments, normal filaments appeared on all grid 
squares examined. Bar, 100 nm. x  110,000. 
in the presence of antibodies M2.1, -2, -4, - 10, - 12, - 15, - 17, - 
18, -19, -22, -26, and control antibodies that do not bind to 
myosin-II. Filaments were observed on all grids inspected (see 
Figs. 4 and 6 for representative micrographs). Thus, antibodies 
tested that bind to the  myosin heads or to the myosin tail 
near its junction with the heads do not inhibit polymerization. 
Similar results were obtained in solutions containing 20 mM 
KC1 with or without 10 mM MgCI2. Thin myosin-II filaments 
formed in the absence of MgC12 and thick myosin-II filaments 
formed in  10 mM MgC12. 
In contrast, two antibodies, M2.3 and -9, are potent inhib- 
itors of myosin-II filament formation (Fig.  6). No filaments 
were ever observed when  monomeric myosin-II was prein- 
cubated with antibodies M2.3, -9, or Fab fragments of M2.3 
before  lowering  the  salt  concentration  to  conditions  that 
would, in the absence of antibody, cause filament formation. 
This inhibition of assembly occurs in 1, 7, and 10 mM MgC12. 
Similarly, M2.3, Fab M2.3, and M2.9 all prevent the side to 
side aggregation of preformed myosin-II thin  filaments into 
thick myosin-II filaments upon the addition of 7 mM MgCI2 
(Fig.  5).  None of the  other antibodies tested prevented the 
formation of thick filaments when diluted into 10 mM MgCI2 
so we  conclude  that  they do  not  interfere  with  the  lateral 
association of thin filaments required to form thick myosin- 
II filaments. Finally, antibodies M2.3  and -9, and Fab frag- 
ments of M2.3 can depolymerize preformed filaments, given 
sufficient time (12).  Antibody-decorated bare zones are only 
observed when specimens are prepared for electron micros- 
copy at  early times  following the  addition  of antibody  to 
preformed filaments. 
DISCUSSION 
Electron  microscopy of myosin-II molecules and  filaments 
reacted with monoclonal antibodies shows directly where the 
antibodies bind and demonstrates that two of the antibodies 
that bind to the tail inhibit the polymerization of myosin-II 
into filaments. These localization studies extend the charac- 
terization  of the  antibodies,  reveal  information  about  the 
arrangement of the myosin-II molecule in the myosin-II fila- 
ment, and provide a structural framework for the interpreta- 
tion  of the  effects of the  antibodies  on  myosin-II function 
both in vitro and in vivo. By combining the direct, electron 
microscope localization of seven antibodies with data from 
peptide mapping and  competitive binding experiments, we 
have established the binding sites of 16 different monoclonal 
antibodies. 
Electron microscopy of antibody-myosin-II complexes di- 
rectly  demonstrate  the  physical  position  of the  antibody- 
binding sites on myosin, while staining of peptide maps or 
the competitive binding experiments can provide more subtle 
information about these sites.  For example, electron micros- 
copy establishes that antibodies M2.3, -9, and -12 all bind at 
the  end  of the  tail,  but  cannot  distinguish  between  their 
binding sites.  Antibody staining of one-dimensional peptide 
maps (10)  provides somewhat better resolution; while M2.3, 
-9, and - 12 stain similar constellations of peptides on some of 
the  maps (M2.3  and  -9  are  similar on  hydroxylamine and 
cyanogen bromide maps, M2.9 and -12 are similar on alpha- 
chymotryptic maps; see Table III in reference 10), and staining 
of the  other  maps  by  these  antibodies  results  in  distinct 
staining  patterns.  Competitive binding  studies  provide the 
best resolution. None of the three antibodies that bind to the 
myosin-II tail inhibits the binding of either of the other two. 
Of the  four  localization  methods,  electron  microscopy of 
negatively stained antibody-filament complexes has the lowest 
resolution,  but  it  provides the  only information  about the 
location  of the  binding  sites  on  myosin-II assembled  into 
filaments. Together the four methods establish the  location 
of the binding sites of all but six of 23 monoclonal antibodies 
to  within  5  or  l0  nm  as  well  as  much  higher  resolution 
information on the relative positions of binding sites within 
the same region. 
Fig. 7 summarizes the localization of the antibody-binding 
sites on myosin-II. These  16 antibodies are members of four 
of the six antibody families defined by peptide mapping and 
competitive binding  studies (10).  Two families bind to the 
heads.  A  large family binds  near the junction  between  the 
heads and the myosin-II tail. In this region some of the family 
members bind to the tail, others to the head. The members 
of the fourth family bind to the tip of the myosin-II tail. We 
have  been  unable  to  localize  members  of the  two  other 
families (M2.5,  -16,  and  -19;  M2.13,  -15,  and  -20),  or the 
binding site of M2.11. 
Two of four antibodies that bind near the end of the tail 
inhibit  polymerization  of myosin-II into  thin  bipolar  fila- 
ments, block the Mg++-induced aggregation of thin myosin- 
II filaments into thick filaments and depolymerize preformed 
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FiGure  7  A schematic of the myosin-II  heavy  chain depicts bind- 
ing sites of the various monodonal antibodies. PO4 designates the 
sites that can be dephosphorylated to allow actin activation of the 
myosin-II Mg+÷-ATPase activity. The 105,000-mol-wt carboxy-ter- 
minus of the heavy chain is shown divided into an 80,000-mol-wt 
region that makes up the 90-nm myosin-II  tail and a 27,000-mol-wt 
region that is in the head. ATP indicates that ATP binds somewhere 
on the 70,000-mol-wt  amino terminal fragment. Antibody numbers 
and brackets show their approximate binding sites. 
thin or thick filaments (see also reference  12). These antibod- 
ies, M2.3 and -9, demonstrate that, as expected, the tail region 
of myosin-II plays a crucial role in filament formation. These 
experiments also illustrate  that monoclonal antibodies can be 
surprisingly  subtle probes of structure-function relationships. 
While antibody M2.12 binds to the end of the myosin-II tail 
by electron microscopy and is, by peptide-staining criteria,  a 
member of the family that includes M2.3 and -9, it does not 
compete with M2.3 or -9 for binding to myosin-II. Nor does 
M2.12 block filament formation like M2.3 and -9. The rea- 
sons for these  differences  will require  further investigation, 
but  these  observations  suggest  that  inhibition  of filament 
formation  requires  antibody  binding  to  key  sites  on  the 
myosin-II tail. 
One of two mechanisms is probably responsible  for anti- 
body inhibition of filament formation. Antibody binding to 
specific  sites  on the  myosin molecule may prevent myosin 
assembly into filaments because of gross steric hindrance or 
because the antibody may alter allosterically  the structure of 
adjacent parts of the tail  that are required for filament for- 
mation.  The  observation  that  Fab  fragments  of M2.3  can 
block polymerization demonstrates that inhibition of  filament 
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formation  is  not  the  result  of nonspecific  aggregation  or 
precipitation of myosin monomer. 
There is little  doubt that the end of the tail  is especially 
important for myosin polymerization, because a 9,000-mol- 
wt region at the carboxy-terminus tip of the myosin-II tail 
contains three serine residues whose phosphorylation inhibits 
the assembly of myosin-II into filaments (3, 4,  13). Antibody 
binding  to  myosin-II may  mimic  phosphorylation  of the 
myosin-II  tail and prevent filament formation for subtle struc- 
tural reasons.  This region is also important for the polymeri- 
zation of muscle myosin where a 5,000-mol-wt region at the 
end of  the muscle myosin tail is responsible for the insolubility 
of light meromyosin at physiological  ionic strength  (15). 
Antibodies in the family that includes M2.4,  -6, -7, and - 
26 bind to the myosin tail near the heads, a region that may 
be homologous to the "hinge" region  of the muscle myosin 
tail. There is some evidence (18) that myosin-II has either no 
or, at the most, a short region comparable to muscle myosin 
subfragment-2.  In  muscle  myosin,  this  alpha-helical  coiled 
coil region of the myosin rod is ~50 nm long and is separated 
from light meromyosin by the hinge region. This hinge region 
contains a proteolytic sensitive site and a region that is struc- 
turally less stable than the remainder of the myosin rod (14, 
21). The hinge region and the flexible joint between  subfrag- 
ment-2 and the subfragment-1  heads,  together with  the pre- 
sumably  passive  subfragment-2  region  allow  the  heads  to 
spread up to 60 nm from the myosin filament backbone. The 
assembled  myosin monomers are stabilized  into bipolar fila- 
ments by lateral  interactions between light meromyosin, the 
distal region of the myosin tail. The subfragment-2 region of 
the muscle myosin molecule is not considered to participate 
in  filament  formation,  and accordingly the  antibodies that 
bind to this short region  of myosin-II do not inhibit polym- 
erization. 
We have been unable to localize a number of the antibody- 
binding sites directly in platinum shadowed specimens.  This 
is consistent with previous attempts to localize the binding of 
antibodies to myosin and spectrin.  Claviez  et al.  (2) report 
localization  of five  of 24  monoclonal  antibodies  directed 
against  Dictyostelium  myosin. Burke and  Shotton (1)  were 
able  to localize  one of four monoclonal antibodies directed 
against  spectrin.  We do not known why the binding sites of 
certain antibodies are  not localized  by our techniques,  but 
speculate that preparation of the antibody-myosin complexes 
for platinum  shadowing might disrupt  antibody binding to 
the myosin molecule.  Winklemann et al. (23) observed  that 
minimizing the  time  between  specimen dilution  and  shad- 
owing improves preservation of myosin-antibody complexes. 
We suspect that dilution, the presence of glycerol required for 
successful specimen preparation and the adsorption of speci- 
mens to mica may all contribute to poor preservation of intact 
antibody-myosin complexes. 
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